Ultragenyx Set to Present at Oppenheimer Healthcare Conference on December 9th

Date Posted:
Dec 3, 2015

Emil D. Kakkis, CEO of Novato-based biopharmaceutical company Ultragenyx is set to present at the Oppenheimer 26th Annual Healthcare Conference on Wednesday, December 9, 2015 at 8:35am ET in New York. The event is described as “one of the most important investor conferences in this sector, providing the first glimpse into the issues and companies that will be prevalent in 2016.” The live and archived webcast of the company presentation will be accessible at this destination on the company’s website.

Ultragenyx recently announced positive interim 40-week data through 40 weeks from the first 36 patients in the ongoing pediatric Phase 2 study of KRN23 for the treatment of X-linked hypophosphatemia (XLH) and the initiation of the Phase 3 study of KRN23 for the treatment of adults with XLH.

For more information on Ultragenyx, including recent clinical study announcements, visit the Ultragenyx website.